Ikena Oncology/IKNA

$1.35

-3.57%
-
1D1W1MYTD1YMAX

About Ikena Oncology

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.

Ticker

IKNA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Manfredi

Employees

34

Headquarters

Boston, United States

Ikena Oncology Metrics

BasicAdvanced
$69M
Market cap
-
P/E ratio
-$1.58
EPS
-
Beta
-
Dividend rate
$69M
$7.38
$1.02
358K
15.849
-43.11%
-48.28%
-46.56%
17.934
0.444
0.444
-78.07%
13.65%
-0.12%

What the Analysts think about Ikena Oncology

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 3 analysts.
517.04% upside
High $11.00
Low $6.00
$1.35
Current price
$8.33
Average price target

Ikena Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100%
Net income
-$16M
-17.01%
Profit margin
0%
-100%

Ikena Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.44
-$0.40
-$0.47
-$0.33
-
Expected
-$0.47
-$0.43
-$0.43
-$0.41
-$0.34
Surprise
-7.25%
-6.98%
9.81%
-20%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ikena Oncology stock?

Ikena Oncology (IKNA) has a market cap of $69M as of May 22, 2024.

What is the P/E ratio for Ikena Oncology stock?

The price to earnings (P/E) ratio for Ikena Oncology (IKNA) stock is 0 as of May 22, 2024.

Does Ikena Oncology stock pay dividends?

No, Ikena Oncology (IKNA) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Ikena Oncology dividend payment date?

Ikena Oncology (IKNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Ikena Oncology?

Ikena Oncology (IKNA) does not currently have a Beta indicator.

What is the Ikena Oncology stock price target?

The target price for Ikena Oncology (IKNA) stock is $8.33, which is 503.62% above the current price of $1.38. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ikena Oncology stock

Buy or sell Ikena Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing